secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001628280-25-017924
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).
- Reported revenue $10.36B (+4.0%), organic sales +6.9% (+8.3% ex-COVID testing).
- Medical Devices sales +9.9% reported (+12.6% organic); FreeStyle Libre revenue $1.7B.
- Full-year 2025 adjusted EPS guidance reaffirmed: $5.05-$5.25; Q2 adj. EPS $1.23-$1.27.
- Volt PFA System received CE Mark; TECTONIC IVL pivotal trial initiated in U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828025017924/0001628280-25-017924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828025017924/abt-20250416.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-017924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer